New combo aims to shrink bile duct tumors before surgery

NCT ID NCT07599995

Not yet recruiting Disease control Sponsor: Sir Run Run Shaw Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving a combination of chemotherapy (gemcitabine and cisplatin) plus an immunotherapy drug (envafolimab) before surgery can reduce tumor cells in patients with bile duct cancer at high risk of recurrence. About 34 adults aged 18-80 with resectable biliary tract cancer will receive the drugs for several cycles, then undergo surgery. The main goal is to see how many patients have a major pathologic response, meaning few or no cancer cells remain in the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gemcitabine, Cisplatin, and Envafolimab
What this could lead to: If successful, this approach could shrink tumors before surgery, potentially lowering the chance of cancer coming back in high-risk patients.
What could go wrong: This is a small, early-phase trial with only 34 participants, so results may not apply broadly. Chemotherapy and immunotherapy can cause serious side effects like low blood counts or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.